Alpha Teknova, Inc. (TKNO) SEC filings

TKNONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/30150% above fair value

$8.29−0.32 (-3.77%)

Close on Nov 12, 2026Market cap $445.34MP/E –Yield –

SEC filings

40 of Alpha Teknova's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Nov 4, 2026	Nov 4, 2026	SEC EDGAR
Current report	8-K	Oct 20, 2026	Oct 21, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Aug 5, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	May 27, 2026	Jun 1, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 4, 2026	May 6, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 21, 2026	Apr 21, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 2, 2026	SEC EDGAR
Current report	8-K	Feb 26, 2026	Feb 26, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 7, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 8, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Jun 17, 2025	Jun 23, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 9, 2025	SEC EDGAR
Current report	8-K	May 8, 2025	May 8, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 17, 2025	Apr 28, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 7, 2025	SEC EDGAR
Current report	8-K	Mar 4, 2025	Mar 4, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 8, 2024	SEC EDGAR
Current report	8-K	Nov 7, 2024	Nov 7, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 13, 2024	SEC EDGAR
Current report	8-K	Aug 13, 2024	Aug 13, 2024	SEC EDGAR
Current report	8-K	Jul 11, 2024	Jul 12, 2024	SEC EDGAR
Current report	8-K	Jul 9, 2024	Jul 9, 2024	SEC EDGAR
Current report	8-K	Jun 26, 2024	Jul 1, 2024	SEC EDGAR
Current report	8-K	Jun 24, 2024	Jun 27, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 13, 2024	SEC EDGAR
Current report	8-K	May 13, 2024	May 13, 2024	SEC EDGAR
Proxy statement	DEF 14A	Jun 24, 2024	Apr 29, 2024	SEC EDGAR
Current report	8-K	Mar 26, 2024	Apr 2, 2024	SEC EDGAR
Annual report	10-K	Dec 31, 2023	Mar 27, 2024	SEC EDGAR
Current report	8-K	Mar 11, 2024	Mar 11, 2024	SEC EDGAR
Current report	8-K	Jan 11, 2024	Jan 16, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2023	Nov 13, 2023	SEC EDGAR
Current report	8-K	Nov 9, 2023	Nov 9, 2023	SEC EDGAR
Current report	8-K	Sep 15, 2023	Sep 19, 2023	SEC EDGAR
Current report	8-K	Aug 8, 2023	Aug 14, 2023	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Alpha Teknova's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TKNO.

Compare: TKNO vs TRIB · TKNO vs ICCC · TKNO vs NTLA · TKNO vs NNNN · TKNO vs AQST

Revenue growth15.4% · median 12.5%

Gross margin36.4% · median 53.1%

Operating margin-32.7% · median -114.1%

Net margin-34.8% · median -162.3%

Company	Revenue	Growth
NTLA	$52.89M	-8.1%
AQST	$48.84M	+12.5%
TKNO	$45.95M	+15.4%
ICCC	$33.21M	+19.6%
TRIB	–	–
NNNN	–	–

Company

Next earnings (est.): Feb 25, 2027, during market hours
Exchange: Nasdaq
Industry: In Vitro & In Vivo Diagnostic Substances
Fiscal year ends: December 31
Employees: 158
Held by institutions: 17.0%
Auditor: GRANT THORNTON LLP
SEC CIK: 1850902

Advertisement
300 × 250

See a number that looks wrong?